Pazopanib

For research use only. Not for use in humans.

製品コードS3012 別名:GW786034

Pazopanib化学構造

CAS No. 444731-52-6

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.

サイズ 価格(税別) 在庫  
JPY 13600 あり
JPY 36800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(51)

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
ターゲット
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
体外試験

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell NEnIPGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoP3TY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIHnjOVA:Oi56OXWtNFUh|ryP M4SyZ3NCVkeHUh?=
human AN3-CA cell M2\4cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVXB[nJbUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> MnPJV2FPT0WU
human CGTH-W-1 cell NXzyRoloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFfGXW5KdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDBwMEGgcm0> NIe4TpJUSU6JRWK=
human GDM-1 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M37CN2lvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFMvQTlibl2= MlTWV2FPT0WU
human A204 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;yTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P NUPUc3pVW0GQR1XS
human G-402 cell M4fxS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7DTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzNU45PCCwTR?= MX3TRW5ITVJ?
human MFE-296 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzie3dKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjV7MEKyJO69VQ>? MWfTRW5ITVJ?
human NOS-1 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1P3fGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhcWN3ME2wMlY2QTh5IN88US=> M{\RNXNCVkeHUh?=
human KG-1 cell NX7jZVNrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1fldmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4PTVizszN MXvTRW5ITVJ?
human HT55 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHu4[ZRKdmirYnn0bY9vKG:oIHj1cYFvKEiWNUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PzhzIN88US=> MW\TRW5ITVJ?
human MG-63 cell NULZ[4RDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3zPcmlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> NYG4O5RiW0GQR1XS
human CCF-STTG1 cell M4DuWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPr[ZBKdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;MT6wOFk5OSEQvF2= NXv4SoxEW0GQR1XS
human RT-112 cell NIPONlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVA{PzZizszN M1rwWXNCVkeHUh?=
human MC-IXC cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\heYNYUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFzNUGyJO69VQ>? MVfTRW5ITVJ?
human HUTU-80 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zpfmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjhzMEOg{txO M3TIXXNCVkeHUh?=
human MV-4-11 cell MknSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4fh[GlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO MXHTRW5ITVJ?
human LCLC-103H cell NVzvZnVYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4jwU2lvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz2xNFNJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[Xl? M2PGWHNCVkeHUh?=
human G-401 cell MlLlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnP0TY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFY1OjFizszN MWTTRW5ITVJ?
human A704 cell MmDmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvtTYpKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxOzJ|IN88US=> MUPTRW5ITVJ?
human ESS-1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= M{\6NnNCVkeHUh?=
human HLE cell MlLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP M2DkbnNCVkeHUh?=
human NY cell NHqxbIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkftTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP NWnhPWxLW0GQR1XS
human A427 cell NXL6UIlWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3HTb2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVgxPzVizszN M4TIXXNCVkeHUh?=
human SK-N-DZ cell NXfZV3U3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzOzhzIN88US=> NXPoVGo2W0GQR1XS
human J82 cell NGjSWJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP MnLYV2FPT0WU
human GI-1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoX0TY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNlk2OSEQvF2= M2\uXnNCVkeHUh?=
human NCI-H716 cell MmrZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnTxTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEexOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzF4M{Og{txO NHznV3JUSU6JRWK=
human SF126 cell NFf1SmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLhXWJnUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd2NUmg{txO M{C1VXNCVkeHUh?=
human H4 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHo[o1KdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= M2rtdXNCVkeHUh?=
human LB831-BLC cell M{Dx[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWLzS4NwUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkW0OVY3KM7:TR?= NEfKXFVUSU6JRWK=
human HCC1395 cell MkfBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoW4TY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42QDF3NjFOwG0> MX;TRW5ITVJ?
human LK-2 cell M{\Cemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFG5cFVKdmirYnn0bY9vKG:oIHj1cYFvKEyNLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlY1PTZ7IN88US=> M4SzeHNCVkeHUh?=
human G-361 cell Mny2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2fNZWlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA1ODh{IN88US=> MYjTRW5ITVJ?
human NCI-H2342 cell NFS4dGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M37lcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:Oy5zM{OxOkDPxE1? M3XLXnNCVkeHUh?=
human SK-LU-1 cell  MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV76VXF3UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? NEPFSHJUSU6JRWK=
human IGROV-1 cell  NU\seI9PT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnWyTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDdzMzFOwG0> NWP5XHlJW0GQR1XS
human EB2 cell MoTjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1LnOWlvcGmkaYTpc44hd2ZiaIXtZY4hTUJ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yPFE3QCEQvF2= MXLTRW5ITVJ?
human CAL-54 cell NYnYbGRkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2naXmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zQDN4NzFOwG0> M3XvfXNCVkeHUh?=
human LB1047-RCC cell M33yfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jpWWlvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OzF|Nkig{txO NHK5OZFUSU6JRWK=
Daudi cell NEf5fHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2X0fGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUOxOlQh|ryP NF\UZ3VUSU6JRWK=
human Daudi cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2G1[2lvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY3OjF7IN88US=> NYe0VWx3W0GQR1XS
human A172 cell MmnUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkezO|kh|ryP M4DhSHNCVkeHUh?=
human KGN cell MmfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjzVHVKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFY4ODlizszN M2T3[HNCVkeHUh?=
human SNG-M cell NV7tTldwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\QVmlvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> NGr6cYxUSU6JRWK=
human SW1710 cell NVjaeHFWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEfhcGhKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDd|MUig{txO NXi4R2xoW0GQR1XS
human HT29 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NHvaW4pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= NH3BXYUyQDZ{MEO4Ni=>
human A375P cells NIfqSpdRem:uaX\ldoF1cW:wIHHzd4F6 NGnIeXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|VRKGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt M2rVelE5PjJyM{iy
human HN5 cells MUDQdo9tcW[ncnH0bY9vKGG|c3H5 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCrbjDz[ZJ2dSClb370ZYlvcW6pIH3l[Il2dQ>? M4rJRlE5PjJyM{iy
HUVEC MYfGeY5kfGmxbjDhd5NigQ>? NUWyNFdoOSEQvF2= M4PLVVYhcA>? NX\ncZVvSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgbY4hUFWYRVOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eYJmKG[xcn3heIlwdiCjdDCwMlEhfU1iYX\0[ZIhPiCqcoOgZpkhVWG2cnnn[Ywh[XO|YYm= NYL3TY5lOjRyM{[wOFI>
human Daoy cell M2fTWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke3PVQ6KM7:TR?= MmflV2FPT0WU
human DMS-273 cell NWTCW4s3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> MVPTRW5ITVJ?
human KU812 cell M2j4T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6zO|gyOiEQvF2= MV\TRW5ITVJ?
human NCI-H727 cell M{TF[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41ODlyMTFOwG0> NIH6dWFUSU6JRWK=
human P30-OHK cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN MX\TRW5ITVJ?
human MIA-PaCa-2 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjHTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? NXrte|F4W0GQR1XS
human TT cell NE\ZdJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHO0eplKdmirYnn0bY9vKG:oIHj1cYFvKFSWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OlI1KM7:TR?= MWnTRW5ITVJ?
human DK-MG cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MorxTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt MkLtV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
体内試験 The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

- 合併
  • 動物モデル: Immunodeficient mice bearing SYO-1 cells
  • 投薬量: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.84 mM) warming
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 437.52
化学式

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
別名 GW786034
Smiles CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04659343 Recruiting Drug: Medical treatment for metastatic renal cell carcinoma Kidney Cancer|Renal Cell Carcinoma Metastatic|Drug Toxicity|Drug Side Effect|Drug Mechanism Frede Donskov|Odense University Hospital|Herlev Hospital|Rigshospitalet Denmark|University of Aarhus November 1 2020 --
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VEGFRシグナル伝達経路

相関VEGFR製品

Tags: Pazopanibを買う | Pazopanib ic50 | Pazopanib供給者 | Pazopanibを購入する | Pazopanib費用 | Pazopanib生産者 | オーダーPazopanib | Pazopanib化学構造 | Pazopanib分子量 | Pazopanib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID